Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab.
Mult Scler
; 30(1): 131-133, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-37888775
ABSTRACT
BACKGROUND:
Late-onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1500/mm3 that develops between 4 weeks and 6 months after the last drug administration, is a rare side effect of anti-CD20 drugs including ocrelizumab. Although continuation of ocrelizumab after LON is not contraindicated, the risk of LON recurrence is not well known. CASES We report three cases of recurrent symptomatic agranulocytosis (ANC < 500/mm3) occurring under ocrelizumab.CONCLUSION:
Given the risk of recurrence of symptomatic agranulocytosis and the availability of other treatments, a therapeutic switch may be discussed after the first episode of LON.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neutropenia
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article